The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
(RTTNews) - Wave Life Sciences (WVE) reported positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback